Abstract
Duloxetine is effective in the management of diabetic peripheral neuropathic pain (DPNP), and may have a better safety and tolerability profile than frequently prescribed tricyclic antidipressants, like amitriptyline. Strategies for switching medications attempt to balance the risk of discontinuation-emergent/treatment-emergent adverse events (AE) with onset of efficacy. This was a multicenter, randomized, double-blind, parallel, 8-week trial in patients with DPNP treated with a stable dose of amitriptyline 25-100 mg/day to compare strategies for switching to duloxetine 60 mg/day.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
